Unique ID issued by UMIN | UMIN000007112 |
---|---|
Receipt number | R000008379 |
Scientific Title | Evaluation of relationships between hepatic steatosis and sleep apnea in subjects suspected to have abdominal obesity, and effects of CPAP treatment on hepatic steatosis. |
Date of disclosure of the study information | 2012/01/21 |
Last modified on | 2014/09/03 20:00:48 |
Evaluation of relationships between hepatic steatosis and sleep apnea in subjects suspected to have abdominal obesity, and effects of CPAP treatment on hepatic steatosis.
Hepatic steatosis, sleep apnea and effects of CPAP therapy.
Evaluation of relationships between hepatic steatosis and sleep apnea in subjects suspected to have abdominal obesity, and effects of CPAP treatment on hepatic steatosis.
Hepatic steatosis, sleep apnea and effects of CPAP therapy.
Japan |
obstructive sleep apnea, hepatic steatosis
Hepato-biliary-pancreatic medicine | Pneumology | Endocrinology and Metabolism |
Others
NO
Hypothesis: Sleep apnea influences hepatic steatosis. CPAP therapy for sleep apnea improves hepatic steatosis.
Efficacy
CT attenuation of liver
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Device,equipment |
CPAP (Continuous Positive Airway Pressure)
20 | years-old | <= |
Not applicable |
Male
(1) Evaluation of relationships between hepatic steatosis and sleep apnea
# Those who underwent polysomnography for suspicion of sleep apnea, and underwent abdominal CT at the time of polysomnography or before the introduction of CPAP (The target sample size is 200).
(2) Evaluation of effects of CPAP on hepatic steatosis
# Those who were introduced CPAP therapy for diagnosis of obstructive sleep apnea by the polysomnography described above.
# Those who were diagnosed to have abdominal obesity at the baseline evaluation.
# Six months or more elapsed from the introduction of CPAP.
# Those who have positive serological HBs antigen, positive serological HCV antibody, or liver disease other than fatty liver.
# Those who have other serious complications.
# Those whose blood BNP levels are 100pg/ml or more.
# Those who take drugs which may cause of hepatic steatosis (amiodarone, methotrexate, systemic steroids, etc.)
40
1st name | |
Middle name | |
Last name | Kazuo Chin |
Kyoto University Graduate School of Medicine
Department of Respiratory Care and Sleep Control Medicine
Shogoin 54, Kawahara-cho, Sakyo-Ku, Kyoto, Japan
075-751-3852
chink@kuhp.kyoto-u.ac.jp
1st name | |
Middle name | |
Last name | Yoshiro Toyama |
Kyoto University Graduate School of Medicine
Department of Respiratory Care and Sleep Control Medicine
Shogoin 54, Kawahara-cho, Sakyo-Ku, Kyoto, Japan
075-751-3852
ytoyama@kuhp.kyoto-u.ac.jp
Kyoto University Graduate School of Medicine, Department of respiratory medicine
Kyoto University Graduate School of Medicine, Department of Respiratory Care and Sleep Control Medicine
Other
NO
2012 | Year | 01 | Month | 21 | Day |
Unpublished
Preinitiation
2012 | Year | 01 | Month | 12 | Day |
2013 | Year | 02 | Month | 01 | Day |
2012 | Year | 01 | Month | 21 | Day |
2014 | Year | 09 | Month | 03 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008379
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |